Skip to main content

ADAG

Stock

ADAG

Stock
Health Care
Biotechnology

Performance overview

ADAG Price
Price Chart

Forward-looking statistics

Beta
0.31
Risk
87.66%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Company info

SectorHealth Care
IndustryBiotechnology
Employees113
Market cap$131.6M

Fundamentals

Enterprise value$48.1M
Revenue$103.2K
Revenue per employee
Profit margin0.00%
Debt to equity36.60

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.74
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$147K
Avg trading volume (10 day)$153K
Put-call ratio

Macro factor sensitivity

Growth+6.1
Credit+32.6
Liquidity-17.5
Inflation+0.1
Commodities+0.7
Interest Rates+0.5

Valuation

Dividend yield0.00%
PEG Ratio-2.68
Price to sales844.47
P/E Ratio-2.68
Enterprise Value to Revenue466.34
Price to book1.73

Upcoming events

Next earnings dayMarch 30, 2022
Next dividend day
Ex. dividend day

News

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year.

Zacks Investment Research (January 8, 2025)
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors

The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab).  The global trial (ADG126-P001 / KEYNOTE-C98) will.

Benzinga (March 16, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free